Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.79 |
| ▸ | FAAH | O00519 | 2/20 | 0.63 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283044 | 0.98 | EPHX1 (0.75) | EPHX1FAAHCASP2EPHX2 | |
| SCHEMBL10645500 | 0.92 | EPHX1 (0.79) | EPHX1FAAHCASP2EPHX2 | |
| SCHEMBL6047100 | 0.91 | EPHX1 (0.68) | EPHX1FAAHEPHX2 | |
| SCHEMBL9763831 | 0.89 | EPHX1 (0.75) | EPHX1FAAHCASP2EPHX2 | |
| SCHEMBL25277850 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25226893 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25275055 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25275041 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25271007 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25227881 | 0.89 | EPHX1 (1.00) | EPHX1CASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | EPHX1 3640/4885FAAH 3870/4885CASP2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.